LAUSR

Objective To assess the clinical efficacy of Morita therapy in combination with pharmacotherapy in adults who were diagnosed with current OCDs. Methods We searched 10 databases to identify articles written in English or Chinese that were published until 15 April 2021. Randomized controlled trials were included. Two authors of this review independently selected the studies, assessed the risk of bias, and extracted the data. Results Twenty-one studies with a total of 1604 participants met the inclusion criteria. Morita therapy plus pharmacotherapy was significantly superior to pharmacotherapy alone in the efficiency of OCD (RR = 1.34, 95% CI: 1.26 to 1.44, I 2 = 0%), and better in reducing OCD severity symptoms (MD = −3.55, 95% CI: −4.34 to −2.75, I 2 = 80%). Conclusion Our meta-analysis and systematic review suggest that Morita therapy may be an effective approach to improve OCDs.